Skip to main content

The study examined and compared re-dosing rates inter alia for human C1 esterase inhibitor in recombinant form (Ruconest®) and plasma-derived forms (Berinert®, Cinryze®) to icatibant (Firazyr®) in seven individual patients at risk of HAE attacks. A total of 69 attacks were recorded. The study was led by Professor Dr Marcus Magerl of the Department of Dermatology and Allergy at the Charité Universitätsmedizin Berlin, Berlin, Germany.  
 

“This was a well-run independent investigator-led comparative study under real world conditions, which gives a clear signal confirming reports from patients.”

- Dr Bruno Giannetti, Pharming’s COO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline